Scynexis bids to end novel antifungal drought, filing ibrexafungerp in USScynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be Share XScynexis bids to end novel antifungal drought, filing ibrexafungerp in UShttps://pharmaphorum.com/news/scynexis-bids-to-end-novel-antifungal-drought/
Novo-backed $61m fundraising helps F2G prep for antifungal launchAnglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening Share XNovo-backed $61m fundraising helps F2G prep for antifungal launchhttps://pharmaphorum.com/news/novo-backed-61m-fundraising-helps-f2g-prep-for-antifungal-launch/
Exclusive Interview with Martin Everett, CSO, Antabio, speaking at Superbugs & SuperdrugsExclusive Interview with Martin Everett Share XExclusive Interview with Martin Everett, CSO, Antabio, speaking at Superbugs & Superdrugshttps://pharmaphorum.com/partner-content/exclusive-interview-with-martin-everett-cso-antabio-speaking-at-superbugs-superdrugs/
Vical slashes staff after culling phase II antifungalUS biotech Vical is planning another round of job cuts after deciding to abandon its antifungal drug VL-2397, Share XVical slashes staff after culling phase II antifungalhttps://pharmaphorum.com/news/vical-staff-culling-phase-ii-antifungal/
